Notícias e Atividades da Adagene

Adagene é uma empresa listada sob o símbolo ADAG (CN).

Veja o organograma con seus 18 executivos principais

Biografias mais buscadas da Adagene

• Peter Luo, Chief Executive Officer and Chairman of The Board
• Andy Cheung, Independent Director
• Zhu Li, Independent Director

Criar um alerta
para seguir os movimentos de executivos da Adagene.

Adagene possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado em 15 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Robert Gould - Board Member da Fulcrum Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Adagene

• News Releases – Adagene Inc.
• Adagene to Participate in Two Upcoming Investor Conferences – Adagene Inc.
• News Releases – Adagene Inc.
• Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types – Adagene Inc.
• Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board – Adagene Inc.
• News Releases – Adagene Inc.
• Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response – Adagene Inc.
• Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update – Adagene Inc.
• Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs – Adagene Inc.
• Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) – Adagene Inc.
• View more press releases Close

Redes sociais sobre Adagene

• Adagene na Wikipedia, Google News e Yahoo Finance
• Adagene na LinkedIn, X (Twitter) e YouTube